Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.765 USD | +0.63% | -8.24% | -21.22% |
May. 10 | HC Wainwright Adjusts 89bio's Price Target to $29 From $31, Maintains Buy Rating | MT |
May. 09 | 89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.22% | 857M | |
+4.58% | 109B | |
+11.70% | 105B | |
+0.76% | 22.25B | |
-11.58% | 22.09B | |
-7.56% | 18.68B | |
-38.36% | 17.58B | |
-10.50% | 16.85B | |
+4.74% | 13.76B | |
+36.89% | 12.46B |
- Stock Market
- Equities
- ETNB Stock
- News 89bio, Inc.
- 89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status